Latest News and Press Releases

PALO ALTO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...

Continue to execute on priority indications for VIP152; recently issued the INN enitociclib IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 still expected in 2H2022 IND...

Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation Clinical data show improved selectivity,...

Prioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL Continuing to advance next-generation modular bioconjugation platform; IND filings for VIP236 in 2H22 and for VIP943 in...

Company to present poster on VIP152 at upcoming European Hematology Association Annual Meeting Presented preliminary findings on VIP152 in gynecologic malignancies in poster at AACR Annual...

VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented for VIP152-treated patients with gynecologic...

Dosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101 Preliminary findings in gynecologic malignancies will be presented as a poster at upcoming AACR Annual Meeting in...

PALO ALTO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...

PALO ALTO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...

VIP236 is a first-in-class anticancer agent, optimized using Vincerx’s proprietary modular bioconjugation platform to target aggressive tumors VIP236 demonstrates promising tumor regression in in...